α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis
M Melde, TM Müller, I Schneider… - Therapeutic …, 2021 - journals.sagepub.com
Background: The anti-α4β7 integrin antibody vedolizumab is an established therapeutic
option for the treatment of inflammatory bowel disease (IBD). It has also been successfully …
option for the treatment of inflammatory bowel disease (IBD). It has also been successfully …
standardising inclusion and outcome criteria for pouchitis—a fragile consensus perhaps but a first step in the right direction.
R Laube, CP Selinger - Alimentary Pharmacology & …, 2021 - search.ebscohost.com
Editorial: standardising inclusion and outcome criteria for pouchitis—a fragile consensus perhaps
but a first step in the righ Page 1 Aliment Pharmacol Ther. 2021;53:1147–1148 …
but a first step in the righ Page 1 Aliment Pharmacol Ther. 2021;53:1147–1148 …
standardising inclusion and outcome criteria for pouchitis—a fragile consensus perhaps but a first step in the right direction. Authors' reply.
Editorial: standardising inclusion and outcome criteria for pouchitis—a fragile consensus
perhaps but a first step in the righ Page 1 Aliment Pharmacol Ther. 2021;53:1149–1150 …
perhaps but a first step in the righ Page 1 Aliment Pharmacol Ther. 2021;53:1149–1150 …
[PDF][PDF] Zaid S Ardalan1, Danny Con2, Sujievvan Chandran3, Jonathan Digby-Bell1, David Gibson1, Alan Pham4, Peter De Cruz3, Kwang Tay5, Stephen Bell6, Miles P …
ZS Ardalan - 2021 - researchgate.net
ABSTRACT Background and Aims: Currently-used endoscopic items for the assessment of
pouchitis and cuffitis have deficiencies in reliability and validation. We assessed the …
pouchitis and cuffitis have deficiencies in reliability and validation. We assessed the …